rs587776802
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM2PM4PP5_Moderate
The NM_006218.4(PIK3CA):c.3203dup(p.Asn1068LysfsTer5) variant causes a frameshift change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Genomes: not found (cov: 32)
Consequence
PIK3CA
NM_006218.4 frameshift
NM_006218.4 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 8.85
Genes affected
PIK3CA (HGNC:8975): (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) Phosphatidylinositol 3-kinase is composed of an 85 kDa regulatory subunit and a 110 kDa catalytic subunit. The protein encoded by this gene represents the catalytic subunit, which uses ATP to phosphorylate PtdIns, PtdIns4P and PtdIns(4,5)P2. This gene has been found to be oncogenic and has been implicated in cervical cancers. A pseudogene of this gene has been defined on chromosome 22. [provided by RefSeq, Apr 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PM4
Frameshift in the end of transcript resulting in stoplost. Downstream stopcodon found after 1204 codons.
PP5
Variant 3-179234358-G-GA is Pathogenic according to our data. Variant chr3-179234358-G-GA is described in ClinVar as [Likely_pathogenic]. Clinvar id is 13658.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PIK3CA | NM_006218.4 | c.3203dup | p.Asn1068LysfsTer5 | frameshift_variant | 21/21 | ENST00000263967.4 | NP_006209.2 | |
PIK3CA | XM_006713658.5 | c.3203dup | p.Asn1068LysfsTer5 | frameshift_variant | 21/21 | XP_006713721.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PIK3CA | ENST00000263967.4 | c.3203dup | p.Asn1068LysfsTer5 | frameshift_variant | 21/21 | 2 | NM_006218.4 | ENSP00000263967 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 31
GnomAD4 exome
Cov.:
31
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:3
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
PIK3CA related overgrowth syndrome Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Clinical Genomics Laboratory, Washington University in St. Louis | Aug 21, 2023 | The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant was identified at an allelic fraction consistent with somatic origin. This variant has been reported in individuals with lung, breast, liver, and bladder cancers (Youssef O et al., PMID: 2819998; Miron A et al., PMID: 20551053; Cizkova Met al., PMID: 22330809; Kachrilas S et al., PMID: 30941989); however, to our knowledge, this variant has not been reported in individuals affected with PIK3CA-Related Overgrowth Spectrum (PROS) disorders. This variant has been reported in multiple cases in the cancer database COSMIC (Genomic Mutation ID: COSV55878665). The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant is absent from the general population (gnomAD v.2.1.1), indicating it is not a common variant. The PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant resides within the C-terminal chain, A1052-A1068, of PIK3CA. This variant results in increased cell proliferation, migration, and Akt phosphorylation compared to wild-type gene product and increased transformation ability in several different cell lines in culture (Jin N et al., PMID: 34779417; Ng PK et al., PMID: 29533785). This variant causes a frameshift by duplicating a single nucleotide; however, because this occurs in the last exon, this is not predicted to lead to nonsense-mediated decay. A large number of PI3K/AKT pathway inhibitors are currently under clinical study in both PROS disorders and cancer (Jin N et al., PMID: 34779417; Venot Q et al., PMID: 29899452; Parker VER et al., PMID: 30270358). Based on an internally-developed protocol informed by the ACMG/AMP guidelines (Richards S et al., PMID: 25741868) and gene-specific practices from the ClinGen Criteria Specification Registry, the PIK3CA c.3203dup (p.Asn1068LysfsTer5) variant is classified as likely pathogenic. - |
Gastric cancer Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 17, 2005 | - - |
Hepatocellular carcinoma Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Feb 17, 2005 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at